These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38491974)

  • 1. Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Lim Fat G; Alibhai S
    Cancer; 2024 Jun; 130(12):2098-2100. PubMed ID: 38491974
    [No Abstract]   [Full Text] [Related]  

  • 2. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Boué A; Joly F; Lequesne J; Lange M
    Cancer; 2024 Jun; 130(12):2120-2138. PubMed ID: 38306301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy and cognitive impairment?
    Bagcchi S
    Lancet Oncol; 2015 Jul; 16(7):e314. PubMed ID: 26004374
    [No Abstract]   [Full Text] [Related]  

  • 4. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study.
    Wu LM; Diefenbach MA; Gordon WA; Cantor JB; Cherrier MM
    Urol Oncol; 2013 Nov; 31(8):1533-8. PubMed ID: 22975107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer.
    Marzouk S; Naglie G; Tomlinson G; Duff Canning S; Breunis H; Timilshina N; Alibhai SMH
    J Urol; 2018 Aug; 200(2):327-334. PubMed ID: 29477720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [When to begin with androgen deprivation?].
    Bex A; Rübben H
    Urologe A; 1998 Mar; 37(2):133-4. PubMed ID: 9563119
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 8. Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Spratt DE; Tward JD
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):899-902. PubMed ID: 32928598
    [No Abstract]   [Full Text] [Related]  

  • 9. New treatment for advanced prostate cancer.
    FDA Consum; 2004; 38(2):4. PubMed ID: 15101352
    [No Abstract]   [Full Text] [Related]  

  • 10. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer drugs. Making sense of the options.
    Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
    Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
    Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An active sex life is possible for men undergoing androgen deprivation therapy for prostate cancer].
    Fode M; Østergren P; Jensen CF; Azawi N; Frey A; Sønksen J
    Ugeskr Laeger; 2015 Jun; 177(24):. PubMed ID: 26058525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis.
    Chao HH; Uchio E; Zhang S; Hu S; Bednarski SR; Luo X; Rose M; Concato J; Li CS
    BMC Cancer; 2012 Aug; 12():371. PubMed ID: 22925152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 19. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Caubet JF
    J Natl Cancer Inst; 1999 Feb; 91(4):381-2. PubMed ID: 10050874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.